Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has reported that the company's Advair Diskus was associated with fewer asthma-related hospitalizations and emergency department visits in pediatric patients when compared to the use of inhaled corticosteroids alone.
Subscribe to our email newsletter
This was an observational study evaluating the rates of asthma-related hospitalizations and emergency department (ED) visits in children four to 11 years of age with persistent asthma. To be considered in the analysis, the child had to have a pharmacy claim for Advair or an inhaled corticosteroid. Medical claims for a four-year period were then examined to see which children had been hospitalized or required treatment in the ED during the year of treatment.
Those using Advair were significantly less likely to have a hospitalization or an ED visit, with asthma-related hospitalizations in the Advair group at three visits per 100 patient-years compared with 4.2 visits per 100 patient-years for the inhaled corticosteroid group (p<0.001) and an asthma-related ED event rate of 15.8 visits per 100 patient-years with those using Advair compared with 18 visits per 100 patient-years for inhaled corticosteroids users (p<0.001).